bevacizumab
roche
['bevacizumab']
adding bevacizumab, an anti-angiogenic drug, to a targeted drug and chemotherapy produced striking activity against her2-positive advanced gastroesopahgeal adenocarcinoma, according to a led clinical trail presented at #aacr23. read more 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090